![Diagnosis and management of secondary-progressive multiple sclerosis: time for change | Neurodegenerative Disease Management Diagnosis and management of secondary-progressive multiple sclerosis: time for change | Neurodegenerative Disease Management](https://www.futuremedicine.com/cms/10.2217/nmt-2019-0024/asset/images/medium/figure1.gif)
Diagnosis and management of secondary-progressive multiple sclerosis: time for change | Neurodegenerative Disease Management
Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)
![Secondary progressive multiple sclerosis: current knowledge and future challenges - The Lancet Neurology Secondary progressive multiple sclerosis: current knowledge and future challenges - The Lancet Neurology](https://www.thelancet.com/cms/attachment/2000998280/2003707685/gr1.jpg)
Secondary progressive multiple sclerosis: current knowledge and future challenges - The Lancet Neurology
![Frontiers | Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure Frontiers | Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure](https://www.frontiersin.org/files/Articles/854390/fneur-13-854390-HTML-r1/image_m/fneur-13-854390-g001.jpg)
Frontiers | Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure
![Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function - The Lancet Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function - The Lancet](https://www.thelancet.com/cms/attachment/eccf8efb-8ccd-4aac-8577-22fa714572f4/gr2_lrg.jpg)